Kilitch Drugs (India) Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mukund Mehta, Managing Director and Promoter of Kilitch Drugs (India), has filed the annual compliance declaration required under SEBI's Takeover Regulations for FY ending 31st March 2025. On behalf of all promoters and the promoter group, he confirmed that no encumbrance (such as pledge, lien, or charge) was created on the shares held by them during the year. This is a routine year-end regulatory filing, not a transaction announcement.
Neutral for shareholders — this is a standard annual compliance confirmation and does not indicate any change in promoter holdings or risk of forced selling from pledged shares.